STOCK TITAN

Alpha Teknova Insider Activity: CFO Receives 169k-Share Option Grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Form 4 filing summary – Alpha Teknova, Inc. (TKNO)

On 02/14/2025 the company granted Chief Financial Officer Matthew Lowell a non-qualified stock option for 169,857 common shares at an exercise price of $8.28 per share. According to the filing, the option vests monthly over 48 equal instalments beginning one month after the grant date and carries an expiration date of 02/14/2035. The transaction is coded “A” (acquired), indicating issuance by the company rather than a market purchase. No non-derivative share transactions were reported.

Following the grant, Lowell directly beneficially owns 169,857 derivative securities; no indirect ownership or additional equity awards were disclosed. The document does not provide information on Teknova’s total shares outstanding, so the potential dilution impact cannot be quantified from the filing alone. There are no sales, open-market purchases, or changes in direct share ownership, and the form contains no amendments to prior reports.

This appears to be a routine element of executive compensation intended to align the CFO’s incentives with long-term shareholder value. Because the award is subject to gradual vesting and requires an $8.28 exercise price, immediate cash outflow from the executive is not involved, nor does the option convey voting rights until exercised.

Positive

  • None.

Negative

  • None.

Insights

TL;DR – Routine CFO option grant; neutral for valuation, limited dilution.

The Form 4 discloses a standard equity-compensation award rather than an opportunistic insider trade. A 169,857-share option at $8.28 aligns the CFO with shareholder interests but does not inject fresh capital or signal management’s market view because no common shares were purchased outright. Without share-count context, dilution appears immaterial; even at 1% of outstanding shares it would not meaningfully shift EPS forecasts until exercised. Vesting over four years encourages retention and long-term performance. Overall, the filing neither alters cash flow nor changes governance risk, so investor impact is neutral.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lowell Matthew

(Last) (First) (Middle)
C/O ALPHA TEKNOVA, INC.
2451 BERT DRIVE

(Street)
HOLLISTER CA 95023

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Alpha Teknova, Inc. [ TKNO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy) $8.28 02/14/2025 A 169,857 (1) 02/14/2035 Common Stock 169,857 $0.0 169,857 D
Explanation of Responses:
1. The number of shares subject to the option shall vest in 48 equal monthly installments on the same day of each month after February 14, 2025, the date of grant.
By: Damon A. Terrill For: Matthew Lowell 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Alpha Teknova

NASDAQ:TKNO

TKNO Rankings

TKNO Latest News

TKNO Latest SEC Filings

TKNO Stock Data

120.98M
10.08M
Drug Manufacturers - Specialty & Generic
In Vitro & in Vivo Diagnostic Substances
Link
United States
HOLLISTER